<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01777347</url>
  </required_header>
  <id_info>
    <org_study_id>IDRCB 2012-A00228-35</org_study_id>
    <secondary_id>P110143</secondary_id>
    <secondary_id>AOM11036</secondary_id>
    <nct_id>NCT01777347</nct_id>
  </id_info>
  <brief_title>Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis</brief_title>
  <acronym>GUERANDE</acronym>
  <official_title>3% Hypertonic Saline to Reduce Hospitalization Rate in Acute Viral Bronchiolitis: a Randomized Double Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nebulized hypertonic saline solution
      reduces the admission rate 48 hours after initial treatment in the emergency department, when
      compared to normal saline solution (control).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute viral bronchiolitis remains a significant cause of hospitalization and to date, no
      treatment reduce the rate of hospitalization. The only accepted treatment for bronchiolitis
      is nasal cleaning, hydration and for hospitalized hypoxemic infants, oxygen administration.

      Several studies shown that nebulization of hypertonic saline solution reduce length of stay
      in hospital for hospitalized infant but effect on rate of hospitalization remains unclear.

      The investigators propose a randomized double blind multicenter clinical trial on infants 6
      weeks to 12 months old with moderate or severe bronchiolitis, in 21 emergency departments of
      hospitals situated France, during 2 winter seasons.

      The investigators hypothesize that infants with bronchiolitis treated with nebulized
      hypertonic 3% saline solution would have less risk of being hospitalized. Our principal
      objective is to determine if nebulized 3% hypertonic saline solution reduces admission rate
      24 hours after treatment compared to placebo.

      Secondary objectives are to compare between groups intensity of respiratory symptoms measured
      by RDAI clinical score, duration of symptoms, length of hospital stay for hospitalized
      infants, adverse effects and health care utilization.

      Patients presenting to the Emergency Department with a diagnosis of moderately severe
      bronchiolitis will be approached for entry into the study. After the initial routine
      assessment, informed consent will be obtained and the infant will be randomized to receive
      treatment in a double-blinded fashion 4 ml of nebulized study solution either 3% hypertonic
      saline (HS, study group) or 0.9% saline (NS, control group) every 20 minutes for a total of 2
      doses. After an observation period of 20 minutes following the last dose, the infant will be
      reassessed by the attending physician in the ER for disposition (admit, discharge home). All
      subsequent therapy, if needed, will be at the sole discretion of the attending physician. The
      family of each recruited subject will be contacted by phone 2, 7, 14 and 28 days later to
      assess resolution of symptoms.

      Clinical response to the above treatment will also be determined independently by the study
      physician utilizing a standardized respiratory scoring system, the Respiratory Distress
      Assessment Instrument (RDAI), at study entry and after each nebulization. The primary outcome
      measure is the rate of admission to hospital between the study and control groups 24 hours
      after inclusion. Secondary outcomes measure will involve the assessment of change in the RDAI
      between study entry and post-treatment, adverse effects, length of stay for hospitalized
      infant and health care utilization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Admission rate</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in RDAI score</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospitalization for hospitalized infant</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health care utilisation</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">778</enrollment>
  <condition>Acute Viral Bronchiolitis</condition>
  <arm_group>
    <arm_group_label>3% Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulized 3% Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nebulized 0.9% normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% Saline</intervention_name>
    <description>Two 4 mL nebulization of 3% saline with 20 minutes interval</description>
    <arm_group_label>3% Saline</arm_group_label>
    <other_name>3% Hypertonic Saline Solution for Inhalation (Mucoclear 3%)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Normal Saline</intervention_name>
    <description>Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval</description>
    <arm_group_label>0.9% Normal Saline</arm_group_label>
    <other_name>0.9% Saline Solution for Inhalation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6 weeks through 12 months

          -  First moderate to severe episode of acute viral bronchiolitis (history of viral upper
             respiratory tract infection plus wheezing and/or crackles on chest auscultation with
             respiratory distress ).

          -  Admission in Emergency Department

          -  Parental/guardian permission (informed consent)

        Exclusion Criteria:

          -  prematurity &lt; 37 weeks

          -  artificial ventilation in the neonatal period

          -  Chronic lung or heart disease

          -  history of immunodeficiency

          -  past use of nebulized HS

          -  initial need for intensive care of assisted ventilation

          -  Non-French speaking parent/guardian
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Gajdos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hôpitaux de Paris - Paris Sud Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mouriez</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Fontainebleau</name>
      <address>
        <city>Fontainebleau</city>
        <zip>77305</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôpital Mère Enfants</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôpital Femme Mère Enfants</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'enfants</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Mère - Enfants</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lenval</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôp Charles Nicolle - CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>André Mignot</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keywords provided by ASSISTANCE PUBLIQUE HOPITAUX DE PARIS:</keyword>
  <keyword>Acute Viral bronchiolitis</keyword>
  <keyword>Hypertonic saline</keyword>
  <keyword>Hospitalization</keyword>
  <keyword>Infants</keyword>
  <keyword>Hospital admissions</keyword>
  <keyword>Additional relevant MeSH terms:</keyword>
  <keyword>Bronchiolitis</keyword>
  <keyword>Bronchiolitis, Viral</keyword>
  <keyword>Bronchial Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Lung Diseases, Obstructive</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis, Viral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 19, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

